Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6013161 | 0.78 | PPARD (0.58) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL26483 | 0.75 | TSHR (1.00) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL282472 | 0.75 | TSHR (0.67) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL5961215 | 0.75 | TSHR (1.00) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL3313657 | 0.75 | PPARD (0.70) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL31574613 | 0.73 | TSHR (0.94) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL9654507 | 0.73 | TSHR (0.63) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL28492909 | 0.73 | TSHR (0.94) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL11745101 | 0.73 | TSHR (0.94) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL29034374 | 0.73 | TSHR (0.94) | TSHRPPARDTP53TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | TSHR 4025/4885PPARD 4259/4885TP53 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.